Oxaliplatin Sensitizes OS Cells to TRAIL-induced Apoptosis Via Down-regulation of Mcl1 |
Huang, Tao
(Department of Orthopedics, The First Affiliated Hospital of China Medical University)
Gong, Wei-Hua (Beth Israel Deaconess Medical Center, Harvard Medical School) Li, Xiu-Cheng (Department of Orthopedics, The First Affiliated Hospital of China Medical University) Zou, Chun-Ping (Department of Orthopedics, The First Affiliated Hospital of China Medical University) Jiang, Guang-Jian (Beth Israel Deaconess Medical Center, Harvard Medical School) Li, Xu-Hui (Beth Israel Deaconess Medical Center, Harvard Medical School) Qian, Hao (Department of Orthopedics, The First Affiliated Hospital of China Medical University) |
1 | Arlt MJ, Walters DK, Banke IJ, et al (2011). The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity. Int J Cancer, 131, E804-12. |
2 | Beaty O, 3rd Berg S, Blaney S, et al (2010). A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer, 55, 440-5. DOI |
3 | Bouralexis S, Findlay DM, Atkins GJ, et al (2003). Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer, 89, 206-14. DOI |
4 | Bruland OS, and Pihl A (1997). On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33, 1725-31. DOI ScienceOn |
5 | Brunat-Mentigny, M., and Kohler, R. (1993). [Osteosarcoma]. Rev Prat, 43, 2197-203. |
6 | Clairambault J, Claude D, Filipski E, Granda T, Levi F (2003). [Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow osteosarcoma induced in mice: a mathematical model]. Pathol Biol (Paris), 51, 212-5. DOI |
7 | Hartmann C, Weinel P, Schmid H, et al (2011). Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. J Pediatr Hematol Oncol, 33, 344-349. DOI |
8 | El Fajoui Z, Toscano F, Jacquemin G et al (2011). Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology, 141, 663-73. DOI |
9 | Geoerger B, Doz F, Gentet JC et al (2008). Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol, 26, 4394-400. DOI |
10 | Gores GJ, Kaufmann SH (2012). Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev, 26, 305-11. DOI |
11 | Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA (2010). Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem, 285, 19162-72. DOI |
12 | Kim J H, Park B, Gupta SC, et al (2012). Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway. Antioxid Redox Signal, 16, 413-27. DOI ScienceOn |
13 | Moon MH, Jeong JK, Seo JS, et al (2011). Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp Mol Med, 43, 138-145. DOI |
14 | Kubista B, Erovic BM, Klinger H, Sulzbacher I, Trieb K (2004). CD9 expression is not a prognostic factor in human osteosarcoma. Cancer Lett, 209, 105-10. DOI |
15 | Lin F, Wang Q, Yu W et al (2011). Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol, 7, 270-5. DOI |
16 | Locklin RM, Federici E, Espina B, et al (2007). Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther, 6, 3219-28. DOI |
17 | Pritchard DM, Berry D, Przemeck SM, et al (2008). Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am J Physiol Gastrointest Liver Physiol, 295, G798-805. DOI |
18 | Rassidakis GZ, Lai R, McDonnell TJ, et al (2002). Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol 160, 2309-10. DOI |
19 | Seol DW (2011). p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun, 416, 222-5. DOI |
20 | Rizza SA, Challagundla KB, Natesampillai S, et al (2011). TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes. PLoS One, 6, e27171. DOI |
21 | Song S, Choi K, Ryu, SW, Kang SW, Choi C (2011). TRAIL promotes caspase-dependent pro-inflammatory responses via PKCdelta activation by vascular smooth muscle cells. Cell Death Dis, 2, e223. DOI |
22 | Takeda S, Iwai A, Nakashima M, et al (2007). LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. Anticancer Res, 27, 761-8. |
23 | Trieb K, Kotz R (2001). Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol, 33, 11-7. DOI |
24 | Zhou W, Hu J, Tang H, et al (2011). Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors. BMC Cancer, 11, 485. DOI |
25 | Van Valen F, Fulda S, Schafer KL, et al (2003). Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer, 107, 929-40. DOI |
26 | Wiley SR, Schooley K, Smolak PJ, et al (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-82. DOI ScienceOn |
27 | Yuan JM, Li XD, Liu ZY, et al (2011). Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev, 12, 3465-9. |
28 | Zhang G, Li M, Jin J, Bai Y, Yang C (2011). Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. Asian Pac J Cancer Prev, 12, 2075-80. |